James Scott, MD
Diagnostic Neuroimaging · Ormond Beach, FLNPI 1952321671
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $19,126 of the $21,822 with a category attached, or 87.6%. It is spread thinly across 60 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations.
Across 992 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- AbbVie$2K
- Biogen$1K
- Pfizer$836
- Sanofi$834
- MDD US Operations, LLC$780
- plus $12K from 54 others
Across 291 payments — averaging $16,233 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3.8M
- EMD Serono, Inc.$297K
- Adamas Pharmaceuticals, Inc.$141K
- Eli Lilly$107K
- Janssen Research & Development, LLC$100K
- Alkermes, Inc.$87K
- plus $172K from 9 others
What the payments were for
- Speaking & faculty fees$3141%
- Travel & lodging$6793%
- Food & beverage$19,12688%
- Education$3362%
- Gifts$1,3676%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few diagnostic neuroimaging providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 121 | $1,225,917 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 42 | $449,147 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $407,523 |
| VumerityDiroximel Fumarate | 34 | $305,855 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 27 | $276,625 |
| CopaxoneGlatiramer Acetate | 40 | $233,321 |
| MayzentSiponimod | 17 | $164,599 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 24 | $132,812 |
| TecfideraDimethyl Fumarate | 12 | $111,072 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $107,456 |
| Austedo XrDeutetrabenazine | 23 | $100,503 |
| GlatopaGlatiramer Acetate | 24 | $87,965 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 21 | $81,657 |
| Dimethyl Fumarate | 72 | $75,536 |
| EliquisApixaban | 85 | $60,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Panzyga, Eliquis | $836 | $549,980119 claims |
| BiogenVumerity, Tecfidera, Avonex (4 Pack) | $1,315 | $524,38359 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $199 | $449,14742 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone, Austedo Xr | $648 | $333,82463 claims |
| NovartisMayzent | $3,455 | $164,59917 claims |
| Grifols USA, LLCGamunex-C | $71 | $132,81224 claims |
| AbbVieUbrelvy, Qulipta | $2,271 | $33,62028 claims |
| Johnson & JohnsonXarelto | $49 | $16,43518 claims |
| UCB, Inc.Neupro | $664 | $15,72716 claims |
| Upsher-smith Laboratories LLCTopiramate | $20 | $4,450233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few diagnostic neuroimaging providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other diagnostic neuroimaging in Ormond Beach
- Dalia FulopOrmond Beach$18K
- David McDonaldOrmond Beach$17K
- Mandeep GarewalOrmond Beach$13K
- Olimpio CunhaOrmond Beach$400
- Michael EspositoTampa$16K
- Anisha GulatiStuart$415
- Jeffrey BongPort St Lucie$317
- Christopher SchaefferLeesburg$51
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.